2,031 results on '"Visser, Pieter Jelle"'
Search Results
2. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies
3. Amyloid-PET imaging predicts functional decline in clinically normal individuals
4. Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles
5. Outcome measures for Alzheimer's disease: A global inter‐societal Delphi consensus
6. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease
7. Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies
8. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease
9. The association of glucose metabolism measures and diabetes status with Alzheimer’s disease biomarkers of amyloid and tau: A systematic review and meta-analysis
10. Augmented reality versus standard tests to assess cognition and function in early Alzheimer’s disease
11. Is the association between blood pressure and cognition in the oldest-old modified by physical, vascular or brain pathology markers? The EMIF-AD 90 + Study
12. Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study
13. Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan
14. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
15. Tear biomarkers for Alzheimer’s disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study
16. Physical activity levels in cognitively normal and cognitively impaired oldest-old and the association with dementia risk factors: a pilot study
17. Discovery of novel CSF biomarkers to predict progression in dementia using machine learning
18. Genetic, vascular and amyloid components of cerebral blood flow in a preclinical population
19. Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
20. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
21. Uncovering social states in healthy and clinical populations using digital phenotyping and Hidden Markov Models
22. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
23. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study
24. Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia
25. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
26. Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis
27. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
28. Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers
29. P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
30. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score
31. Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia
32. Costs of diagnosing early Alzheimer's disease in three European memory clinic settings: Results from the precision medicine in Alzheimer's disease project.
33. Detecting functional decline from normal ageing to dementia: development and validation of a short version of the Amsterdam IADL Questionnaire
34. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
35. Genetic overlap between Alzheimer's disease and blood lipid levels
36. Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42
37. The Dementias Platform UK (DPUK) Data Portal
38. Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study
39. A methodology for cohort harmonisation in multicentre clinical research
40. Duration of Care Trajectories in Persons With Dementia Differs According to Demographic and Clinical Characteristics
41. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status
42. Contributions of amyloid beta and cerebral small vessel disease in clinical decline
43. Longitudinal tau binding in tau‐PET negative patients with clinical Alzheimer’s disease
44. Amyloid‐PET Centiloid quantification predicts cognitive functioning in a pre‐dementia population: findings from AMYPAD‐PNHS
45. Proteomics correlates of amyloid beta and tau in CSF: A monozygotic twin study
46. Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort
47. APOE‐dependent and ‐independent polygenic pathways determining early Alzheimer’s Disease pathological changes in CSF and MRI
48. Hyperspectral retinal imaging as a biomarker for Alzheimer’s disease
49. Differential associations between regional amyloid PET and Alzheimer’s disease polygenic risk scores
50. The association between Aβ aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.